Tucidinostat
- Generic Name
- Tucidinostat
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19FN4O2
- CAS Number
- 1616493-44-7
- Unique Ingredient Identifier
- 87CIC980Y0
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
- Conditions
- Peripheral T-cell Lymphoma Targeted Therapy
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Target Recruit Count
- 200
- Registration Number
- NCT05678933
- Locations
- 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China
Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
- Conditions
- HR+/HER2- Breast Cancer
- Interventions
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05633914
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 47
- Registration Number
- NCT05632848
- Locations
- 🇨🇳
Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, China
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
- Conditions
- HR+/HER2- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05586841
- Locations
- 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
- Conditions
- Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 47
- Registration Number
- NCT05572983
- Locations
- 🇨🇳
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
- Conditions
- Acute Monocytic LeukemiaNewly Diagnosed
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 92
- Registration Number
- NCT05566054
- Locations
- 🇨🇳
The First Affliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Umbrella Study in R/R PTCL Guided by Molecular Subtypes
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT05559008
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT05519865
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 43
- Registration Number
- NCT05478473
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
ChiCGB vs BEAM in High-risk or R/R Lymphomas
- Conditions
- Lymphoma, Large B-Cell, DiffuseLymphoma, T-Cell
- Interventions
- Procedure: Autologous hematopoietic stem cell transplant
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 306
- Registration Number
- NCT05466318
- Locations
- 🇨🇳
Chengdu Third People's Hospital, Chendu, Sichuan, China
🇨🇳People's Hospital of Deyang City, Deyang, Deyang, China
🇨🇳West China Hospital, Sichuan University, Chendu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.